Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma
Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblastoma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aqueous solubility and undesirable side effects limit its clinical application, including local treat...
Saved in:
Main Authors: | , , , , , |
---|---|
格式: | 图书 |
出版: |
Taylor & Francis Group,
2018-01-01T00:00:00Z.
|
主题: | |
在线阅读: | Connect to this object online. |
标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
成为第一个发表评论!